(MENAFN- GlobeNewsWire - Nasdaq) AUSTIN, Texas, Oct.08, 2019(GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women's health company focused on gynecologic disease, today announced that it will report financial results for the three and nine months ended September 30, 2019 on Tuesday, November 12th, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Tuesday, November 12th @ 4:30pm Eastern Time
|
| Domestic: | | 877-407-4018 |
| International: | | 201-689-8471 |
| Conference ID: | | 13695174 |
| Webcast: | | http://public.viavid.com/index.php?id=136364 |
About Vermillion, Inc.
Vermillion, Inc. is dedicated to the discovery; development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use.
Visitwww.vermillion.comor more information.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
MENAFN0910201900703653ID1099102139
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.